Identification of EGFR mutation status in male patients with non-small-cell lung cancer: role of 18F-FDG PET/CT and serum tumor markers CYFRA21-1 and SCC-Ag

Siegel RL, Miller KD, Fuchs HE, Jemal A. Cancer statistics, 2022. CA Cancer J Clin. 2022;72(1):7–33. https://doi.org/10.3322/caac.21708.

Article  PubMed  Google Scholar 

Torre LA, Bray F, Siegel RL, Ferlay J, Lortet-Tieulent J, Jemal A. Global cancer statistics, 2012. CA Cancer J Clin. 2015;65(2):87–108. https://doi.org/10.3322/caac.21262.

Article  PubMed  Google Scholar 

Minguet J, Smith KH, Bramlage P. Targeted therapies for treatment of non-small cell lung cancer—recent advances and future perspectives. Int J Cancer. 2016;138(11):2549–61. https://doi.org/10.1002/ijc.29915.

Article  CAS  PubMed  Google Scholar 

Wu YL, Saijo N, Thongprasert S, Yang JC, Han B, Margono B, et al. Efficacy according to blind independent central review: Post-hoc analyses from the phase III, randomized, multicenter, IPASS study of first-line gefitinib versus carboplatin/paclitaxel in Asian patients with EGFR mutation-positive advanced NSCLC. Lung Cancer. 2017;104:119–25. https://doi.org/10.1016/j.lungcan.2016.11.022.

Article  PubMed  Google Scholar 

Leighl NB, Rekhtman N, Biermann WA, Huang J, Mino-Kenudson M, Ramalingam SS, et al. Molecular testing for selection of patients with lung cancer for epidermal growth factor receptor and anaplastic lymphoma kinase tyrosine kinase inhibitors: American Society of Clinical Oncology endorsement of the College of American Pathologists/International Association for the study of lung cancer/association for molecular pathology guideline. J Clin Oncol. 2014;32(32):3673–9. https://doi.org/10.1200/JCO.2014.57.3055.

Article  PubMed  PubMed Central  Google Scholar 

Hosgood HD 3rd, Pao W, Rothman N, Hu W, Pan YH, Kuchinsky K, et al. Driver mutations among never smoking female lung cancer tissues in China identify unique EGFR and KRAS mutation pattern associated with household coal burning. Respir Med. 2013;107(11):1755–62. https://doi.org/10.1016/j.rmed.2013.08.018.

Article  PubMed  Google Scholar 

Yang SY, Yang TY, Chen KC, Li YJ, Hsu KH, Tsai CR, et al. EGFR L858R mutation and polymorphisms of genes related to estrogen biosynthesis and metabolism in never-smoking female lung adenocarcinoma patients. Clin Cancer Res. 2011;17(8):2149–58. https://doi.org/10.1158/1078-0432.CCR-10-2045.

Article  CAS  PubMed  Google Scholar 

Choi YH, Lee JK, Kang HJ, Lee TS, Kim HR, Kim CH, et al. Association between age at diagnosis and the presence of EGFR mutations in female patients with resected non-small cell lung cancer. J Thorac Oncol. 2010;5(12):1949–52. https://doi.org/10.1097/jto.0b013e3181f38816.

Article  PubMed  Google Scholar 

Subramanian J, Govindan R. Molecular genetics of lung cancer in people who have never smoked. Lancet Oncol. 2008;9(7):676–82. https://doi.org/10.1016/S1470-2045(08)70174-8.

Article  CAS  PubMed  Google Scholar 

Sun PL, Seol H, Lee HJ, Yoo SB, Kim H, Xu X, et al. High incidence of EGFR mutations in Korean men smokers with no intratumoral heterogeneity of lung adenocarcinomas: correlation with histologic subtypes, EGFR/TTF-1 expressions, and clinical features. J Thorac Oncol. 2012;7(2):323–30. https://doi.org/10.1097/JTO.0b013e3182381515.

Article  CAS  PubMed  Google Scholar 

Jiang M, Zhang X, Chen Y, Chen P, Guo X, Ma L, et al. A review of the correlation between epidermal growth factor receptor mutation status and (18)F-FDG metabolic activity in non-small cell lung cancer. Front Oncol. 2022;12:780186. https://doi.org/10.3389/fonc.2022.780186.

Kirchner J, Sawicki LM, Nensa F, Schaarschmidt BM, Reis H, Ingenwerth M, et al. Prospective comparison of (18)F-FDG PET/MRI and (18)F-FDG PET/CT for thoracic staging of non-small cell lung cancer. Eur J Nucl Med Mol Imaging. 2019;46(2):437–45. https://doi.org/10.1007/s00259-018-4109-x.

Article  CAS  PubMed  Google Scholar 

Kim YI, Paeng JC, Park YS, Cheon GJ, Lee DS, Chung JK, et al. Relation of EGFR mutation status to metabolic activity in localized lung adenocarcinoma and its influence on the use of FDG PET/CT parameters in prognosis. AJR Am J Roentgenol. 2018;210(6):1346–51. https://doi.org/10.2214/AJR.17.18916.

Article  PubMed  Google Scholar 

Guo Y, Zhu H, Yao Z, Liu F, Yang D. The diagnostic and predictive efficacy of (18)F-FDG PET/CT metabolic parameters for EGFR mutation status in non-small-cell lung cancer: a meta-analysis. Eur J Radiol. 2021;141:109792. https://doi.org/10.1016/j.ejrad.2021.109792.

Tanaka K, Hata A, Kaji R, Fujita S, Otoshi T, Fujimoto D, et al. Cytokeratin 19 fragment predicts the efficacy of epidermal growth factor receptor-tyrosine kinase inhibitor in non-small-cell lung cancer harboring EGFR mutation. J Thorac Oncol. 2013;8(7):892–8. https://doi.org/10.1097/JTO.0b013e31828c3929.

Article  CAS  PubMed  Google Scholar 

Fiala O, Pesek M, Finek J, Benesova L, Minarik M, Bortlicek Z, et al. Predictive role of CEA and CYFRA 21-1 in patients with advanced-stage NSCLC treated with erlotinib. Anticancer Res. 2014;34(6):3205–10.

CAS  PubMed  Google Scholar 

Liu L, Xiong X. Clinicopathologic features and molecular biomarkers as predictors of epidermal growth factor receptor gene mutation in non-small cell lung cancer patients. Curr Oncol. 2021;29(1):77–93. https://doi.org/10.3390/curroncol29010007.

Article  PubMed  PubMed Central  Google Scholar 

Jin B, Dong Y, Wang HM, Huang JS, Han BH. Correlation between serum CEA levels and EGFR mutations in Chinese nonsmokers with lung adenocarcinoma. Acta Pharmacol Sin. 2014;35(3):373–80. https://doi.org/10.1038/aps.2013.164.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Wen L, Wang S, Xu W, Xu X, Li M, Zhang Y, et al. Value of serum tumor markers for predicting EGFR mutations in non-small cell lung cancer patients. Ann Diagn Pathol. 2020;49:151633. https://doi.org/10.1016/j.anndiagpath.2020.151633.

Cai Z. Relationship between serum carcinoembryonic antigen level and epidermal growth factor receptor mutations with the influence on the prognosis of non-small-cell lung cancer patients. Oncol Targets Ther. 2016;9:3873–8. https://doi.org/10.2147/OTT.S102199.

Article  CAS  Google Scholar 

Wang S, Ma P, Ma G, Lv Z, Wu F, Guo M, et al. Value of serum tumor markers for predicting EGFR mutations and positive ALK expression in 1089 Chinese non-small-cell lung cancer patients: a retrospective analysis. Eur J Cancer. 2020;124:1–14. https://doi.org/10.1016/j.ejca.2019.10.005.

Article  CAS  PubMed  Google Scholar 

Kawaguchi T, Takada M, Kubo A, Matsumura A, Fukai S, Tamura A, et al. Gender, histology, and time of diagnosis are important factors for prognosis: analysis of 1499 never-smokers with advanced non-small cell lung cancer in Japan. J Thorac Oncol. 2010;5(7):1011–7. https://doi.org/10.1097/JTO.0b013e3181dc213e.

Article  PubMed  Google Scholar 

Na II, Byun BH, Kang HJ, Cheon GJ, Koh JS, Kim CH, et al. 18F-fluoro-2-deoxy-glucose uptake predicts clinical outcome in patients with gefitinib-treated non-small cell lung cancer. Clin Cancer Res. 2008;14(7):2036–41. https://doi.org/10.1158/1078-0432.CCR-07-4074.

Article  CAS  PubMed  Google Scholar 

Lee EY, Khong PL, Lee VH, Qian W, Yu X, Wong MP. Metabolic phenotype of stage IV lung adenocarcinoma: relationship with epidermal growth factor receptor mutation. Clin Nucl Med. 2015;40(3):e190-195. https://doi.org/10.1097/RLU.0000000000000684.

Article  PubMed  Google Scholar 

Yang G, Yang Y, Hu J, Xu H, Zhang S, Wang Y. EGFR exon 20 insertion variants A763_Y764insFQEA and D770delinsGY confer favorable sensitivity to currently approved EGFR-specific tyrosine kinase inhibitors. Front Pharmacol. 2022;13:984503. https://doi.org/10.3389/fphar.2022.984503.

Xue J, Li B, Wang Y, Huang Z, Liu X, Guo C, et al. Efficacy and safety of epidermal growth factor receptor (EGFR)-tyrosine kinase inhibitor combination therapy as first-line treatment for patients with advanced EGFR-mutated, non-small cell lung cancer: a systematic review and bayesian network meta-analysis. Cancers (Basel). 2022;14 (19). https://doi.org/10.3390/cancers14194894.

Tan CS, Gilligan D, Pacey S. Treatment approaches for EGFR-inhibitor-resistant patients with non-small-cell lung cancer. Lancet Oncol. 2015;16(9):e447–59. https://doi.org/10.1016/S1470-2045(15)00246-6.

Article  CAS  PubMed  Google Scholar 

Lindeman NI, Cagle PT, Beasley MB, Chitale DA, Dacic S, Giaccone G, et al. Molecular testing guideline for selection of lung cancer patients for EGFR and ALK tyrosine kinase inhibitors: guideline from the College of American Pathologists, International Association for the Study of Lung Cancer, and Association for Molecular Pathology. J Mol Diagn. 2013;15(4):415–53. https://doi.org/10.1016/j.jmoldx.2013.03.001.

Article  CAS  PubMed  Google Scholar 

Lv Z, Fan J, Xu J, Wu F, Huang Q, Guo M, et al. Value of (18)F-FDG PET/CT for predicting EGFR mutations and positive ALK expression in patients with non-small cell lung cancer: a retrospective analysis of 849 Chinese patients. Eur J Nucl Med Mol Imaging. 2018;45(5):735–50. https://doi.org/10.1007/s00259-017-3885-z.

Article  CAS  PubMed  Google Scholar 

Sun YH, Fang R, Gao B, Han XK, Zhang JH, Pao W, et al. Comparable rate of EGFR kinase domain mutation in lung adenocarcinomas from Chinese male and female never-smokers. Acta Pharmacol Sin. 2010;31(5):647–8. https://doi.org/10.1038/aps.2010.43.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Chung JH, Kim T, Kang YJ, Yoon SH, Kim YS, Lee SK, et al. PAK1 as a potential therapeutic target in male smokers with EGFR-mutant non-small cell lung cancer. Molecules. 2020;25(23). https://doi.org/10.3390/molecules25235588.

Varadhachary GR, Abbruzzese JL, Lenzi R. Diagnostic strategies for unknown primary cancer. Cancer. 2004;100(9):1776–85. https://doi.org/10.1002/cncr.20202.

Article  CAS  PubMed  Google Scholar 

Cedres S, Nunez I, Longo M, Martinez P, Checa E, Torrejon D, et al. Serum tumor markers CEA, CYFRA21-1, and CA-125 are associated with worse prognosis in advanced non-small-cell lung cancer (NSCLC). Clin Lung Cancer. 2011;12(3):172–9. https://doi.org/10.1016/j.cllc.2011.03.019.

Article  CAS  PubMed  Google Scholar 

Wu Z, Dai Y, Chen LA. The prediction of epidermal growth factor receptor mutation and prognosis of EGFR tyrosine kinase inhibitor by serum ferritin in advanced NSCLC. Cancer Manag Res. 2019;11:8835–43. https://doi.org/10.2147/CMAR.S216037.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Peng L, Du B, Cui Y, Luan Q, Li Y, Li X. (18)F-FDG PET/CT for assessing heterogeneous metabolic response between primary tumor and metastases and prognosis in non-small cell lung cancer. Clin Lung Cancer. 2022;23(7):608–19. https://doi.org/10.1016/j.cllc.2022.08.001.

Article  CAS  PubMed  Google Scholar 

Marcus C, Tajmir SH, Rowe SP, Sheikhbahaei S, Solnes LB. (18)F-FDG PET/CT for response assessment in lung cancer. Semin Nucl Med. 2022;52(6):662–72. https://doi.org/10.1053/j.semnuclmed.2022.04.001.

Article  PubMed  Google Scholar 

Shang J, You H, Dong C, Li Y, Cheng Y, Tang Y, et al. Predictive value of baseline metabolic tumor burden on (18)F-FDG PET/CT for brain metastases in patients with locally advanced non-small-cell lung cancer. Front Oncol. 2022;12:1029684. https://doi.org/10.3389/fonc.2022.1029684.

Article  PubMed  PubMed Central  Google Scholar 

Na II, Byun BH, Kim KM, Cheon GJ, du Choe H, Koh JS, et al. 18F-FDG uptake and EGFR mutations in patients with non-small cell lung cancer: a single-institution retrospective analysis. Lung Cancer. 2010;67(1):76–80. https://doi.org/10.1016/j.lungcan.2009.03.010.

Article 

留言 (0)

沒有登入
gif